A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early-Stage Parkinson's Disease
Hoffmann-La Roche
900 participants
Nov 24, 2025
INTERVENTIONAL
Conditions
Summary
The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics (PK) of prasinezumab compared with placebo in participants with early-stage Parkinson's disease (PD) on stable symptomatic monotherapy with levodopa.
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Participants will receive Prasinezumab as an IV Infusion as per the schedule mentioned in the protocol.
Participants will receive Placebo as an IV Infusion per the schedule mentioned in the protocol
Locations(101)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07174310